Sarcoma — Trials · CancerIndex

Clinical trials

Registered studies

2,687 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 634
Recruiting: 364
Ph III recruiting: 20
Growth YoY: −14.6%
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (365)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03994627	Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma	approved for marketing	—	—	Eli Lilly and CompanyINDUSTRY	11	Dec 16, 2024	clinicaltrials

Data updated 22 days agoSource updated Dec 16, 2024source: clinicaltrials